International Stem Cell (ISCO) Enterprise Value (2010 - 2026)
International Stem Cell (ISCO) posted quarterly Enterprise Value of -$993000.0 for Q4 2025, up 19.27% year-over-year from -$832576.7 in Q4 2024, and down 2.8% quarter-over-quarter from -$966000.0 in Q3 2025.
International Stem Cell (ISCO) Enterprise Value (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Enterprise Value for 16 consecutive years, with -$993000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Enterprise Value rose 19.27% year-over-year to -$993000.0; the TTM figure through Dec 2025 stood at -$993000.0 (up 19.27% YoY), while the FY2025 annual figure was -$993000.0, up 19.27% from the prior year.
- Enterprise Value eased to -$993000.0 in Q4 2025 per ISCO's latest filing, from -$966000.0 in the prior quarter.
- Across five years, Enterprise Value topped out at -$171000.0 in Q4 2021 and bottomed at -$1.6 million in Q4 2023.
- Historically, Enterprise Value has averaged -$955000.0 across 5 years, with a median of -$979500.0 in 2025.
- Annual changes were most pronounced in 2022 — Enterprise Value plunged 333.92% — and 2025, when it jumped 84.65%.
- International Stem Cell's Enterprise Value stood at -$171000.0 in 2021, then slumped by 333.92% to -$742000.0 in 2022, then slumped by 114.02% to -$1.6 million in 2023, then grew by 22.54% to -$1.2 million in 2024, then advanced by 19.27% to -$993000.0 in 2025.
- Business Quant data shows ISCO's Enterprise Value at -$993000.0 in Q4 2025, -$966000.0 in Q3 2025, and -$198000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn | -1.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.09 Mn |
| Dec 31, 2025 | -993,000.00 |
| Sep 30, 2025 | -966,000.00 |
| Jun 30, 2025 | -198,000.00 |
| Mar 31, 2025 | -1.45 Mn |
| Dec 31, 2024 | -1.23 Mn |
| Sep 30, 2024 | -1.31 Mn |
| Jun 30, 2024 | -1.29 Mn |
| Mar 31, 2024 | -1.39 Mn |
| Dec 31, 2023 | -1.59 Mn |
| Sep 30, 2023 | -1.43 Mn |
| Jun 30, 2023 | -1.38 Mn |
| Mar 31, 2023 | -943,000.00 |
| Dec 31, 2022 | -742,000.00 |
| Sep 30, 2022 | -666,000.00 |
| Jun 30, 2022 | -586,000.00 |
| Mar 31, 2022 | -398,000.00 |
| Dec 31, 2021 | -171,000.00 |
| Sep 30, 2021 | -505,000.00 |
| Jun 30, 2021 | -750,000.00 |